The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
New molecular and biochemical insights of doxorubicin-induced hepatotoxicity
Abstract
Chemotherapeutic antibiotic doxorubicin belongs to the anthracycline class, slaughters not only the cancer cells but also non-cancerous cells even in the non-targeted organs thereby resulting in the toxicity. The liver is primarily involved in the process of detoxification and this mini-review we focused mainly to investigate the molecular mechanisms heading hepatotoxicity caused due to doxorubicin administration. The alterations in the doxorubicin treated liver tissue include vacuolation of hepatocytes, degeneration of hepatocyte cords, bile duct hyperplasia and focal necrosis. About the literature conducted, hepatotoxicity caused by doxorubicin has been explained by estimating the levels of liver serum biomarkers, ROS production, antioxidant enzymes, lipid peroxidation, and mitochondrial dysfunction. The liver serum biomarkers such as ALT and AST, elated levels of free radicals inducing oxidative stress characterized by a surge in Nrf-2, FOXO-1 and HO-1 genes and diminution of anti-oxidant activity characterized by a decline in SOD, GPx, and CAT genes. The augmented levels of SGOT, SGPT, LDH, creatine kinase, direct and total bilirubin levels also reveal the toxicity in the hepatic tissue due to doxorubicin treatment. The molecular insight of hepatotoxicity is mainly due to the production of ROS, ameliorated oxidative stress and inflammation, deteriorated mitochondrial production and functioning, and enhanced apoptosis. Certain substances such as extracts from medicinal plants, natural products, and chemical substances have been shown to produce an alleviating effect against the doxorubicin-induced hepatotoxicity are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Tacar, O., Sriamornsak, P., & Dass, C. R. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01567.x · Cited by 2,465
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Wink, D. A., & Mitchell, J. B. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00092-6 · Cited by 1,606
Betteridge, D. J. (2000) · Metabolism · doi:10.1016/s0026-0495(00)80077-3 · Cited by 1,455
Toxic proteins released from mitochondria in cell death
Saelens, X., Festjens, N., Walle, L. V., Gurp, M. V., Loo, G. V., & Vandenabeele, P. (2004) · Oncogene · doi:10.1038/sj.onc.1207523 · Cited by 986
An overview of doxorubicin formulations in cancer therapy
Rivankar, S. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.139267 · Cited by 748
Enomoto, A. (2001) · Toxicological Sciences · doi:10.1093/toxsci/59.1.169 · Cited by 728
Nitric oxide and cancer: a review
Korde Choudhari, S., Chaudhary, M., Bagde, S., Gadbail, A. R., & Joshi, V. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-118 · Cited by 634
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
Walczak, H., & Krammer, P. H. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4840 · Cited by 628
Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Self-citationBiological aspects of reactive nitrogen species
Patel, R. P., McAndrew, J., Sellak, H., White, C. R., Jo, H., Freeman, B. A., & Darley-Usmar, V. M. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00028-6 · Cited by 498
Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death?
Candé, C., Cecconi, F., Dessen, P., & Kroemer, G. (2002) · Journal of Cell Science · doi:10.1242/jcs.00210 · Cited by 491
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
Fornari, F. A., Randolph, J. K., Yalowich, J. C., Ritke, M. K., & Gewirtz, D. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10149-1 · Cited by 436
Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells.
Momparler, R. L., Karon, M. R., Siegel, S. E., & Avila, F. (1976) · PubMed · Cited by 423
Polyphenols in Human Health and Disease
(2014) · Elsevier eBooks · doi:10.1016/c2011-1-09286-x · Cited by 419
Lin, Q., Weis, S., Yang, G., Weng, Y.-H., Helston, R., Rish, K., Smith, A., Bordner, J., Polte, T., Gaunitz, F., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607954200 · Cited by 416
Boswellia serrata, a potential antiinflammatory agent: an overview.
Siddiqui, M. (2011) · PubMed · doi:10.4103/0250-474x.93507 · Cited by 388
Antioxidant nutrients and adriamycin toxicity
Quiles, J. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00383-9 · Cited by 362
Role of anthracyclines in the era of targeted therapy
Cortés-Funes, H., & Coronado, C. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0015-3 · Cited by 294
Doroshow, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4514 · Cited by 269
Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats
Kalender, Y., Yel, M., & Kalender, S. (2005) · Toxicology · doi:10.1016/j.tox.2004.12.003 · Cited by 247
Mechanisms of doxorubicin resistance in hepatocellular carcinoma
Cox, J., & Weinman, S. (2016) · Hepatic Oncology · doi:10.2217/hep.15.41 · Cited by 187
Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver
Kassner, N., Huse, K., Martin, H.-J., Gödtel-Armbrust, U., Metzger, A., Meineke, I., Brockmöller, J., Klein, K., Zanger, U. M., Maser, E., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022251 · Cited by 180
Injac, R., Perse, M., Obermajer, N., Djordjevic-Milic, V., Prijatelj, M., Djordjevic, A., Cerar, A., & Strukelj, B. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.04.048 · Cited by 167
Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes
Hickok, J. R., & Thomas, D. D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790232149 · Cited by 158
Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes
Lopez, M., Soler, F., Pascual-Figal, D. A., Fernández-Belda, F., & Lax, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172803 · Cited by 157
Song, S., Chu, L., Liang, H., Chen, J., Liang, J., Huang, Z., Zhang, B., & Chen, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01030 · Cited by 156
Quercetin Potentiates Doxorubicin Mediated Antitumor Effects against Liver Cancer through p53/Bcl-xl
Wang, G., Zhang, J., Liu, L., Sharma, S. P., & Dong, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051764 · Cited by 151
An evaluation of hepatotoxicity in breast cancer patients receiving injection doxorubicin
Damodar, G., Smitha, T., Gopinath, S., Vijayakumar, S., & Rao, Y. (2014) · Annals of Medical and Health Sciences Research · doi:10.4103/2141-9248.126619 · Cited by 134
A study on the toxic effects of doxorubicin on the histology of certain organs
Reddy, A., Anjaneyulu, Y., Shivakumar, P., & Rani, M. (2012) · Toxicology International · doi:10.4103/0971-6580.103656 · Cited by 127
Lv, L., Zheng, L., Dong, D., Xu, L., Yin, L., Xu, Y., Qi, Y., Han, X., & Peng, J. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.012 · Cited by 119
Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity
El‐Moselhy, M. A., & El‐Sheikh, A. A. K. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.09.001 · Cited by 115
Protective Effects of Erdosteine on Doxorubicin-induced Hepatotoxicity in Rats
Yağmurca, M., Baş, O., Mollaoğlu, H., et al. (2007) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.01.007 · Cited by 114
Antioxidant Role of Catechin in Health and Disease
Zanwar, A. A., Badole, S. L., Shende, P., Hegde, M. V., & Bodhankar, S. L. (2013) · Polyphenols in Human Health and Disease · doi:10.1016/b978-0-12-398456-2.00021-9 · Cited by 111
Fulda, S., & Debatin, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209518 · Cited by 107
Protective Effects of Berberine on Doxorubicin-Induced Hepatotoxicity in Mice
Zhao, X., Zhang, J., Tong, N., Chen, Y., & Luo, Y. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.35.796 · Cited by 105
Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel
Pieniążek, A., Czepas, J., Piasecka‐Zelga, J., Gwoździński, K., & Koceva‐Chyła, A. (2013) · Advances in Medical Sciences · doi:10.2478/v10039-012-0063-1 · Cited by 105
Barakat, B. M., Ahmed, H. I., Bahr, H. I., & Elbahaie, A. M. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8296451 · Cited by 105
THE HEPATIC PHARMACOKINETICS OF DOXORUBICIN AND LIPOSOMAL DOXORUBICIN
Hilmer, S. N., Cogger, V. C., Muller, M., & Couteur, D. G. L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.794 · Cited by 99
Qian, H., Yang, Y., & Wang, X.-F. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.04.002 · Cited by 96
Sasame, H. A., & Boyd, M. R. (1979) · Life Sciences · doi:10.1016/0024-3205(79)90042-0 · Cited by 85
Subapriya, R., Kumaraguruparan, R., Ramachandran, C. R., & Nagini, S. (2002) · Clinical Biochemistry · doi:10.1016/s0009-9120(02)00340-5 · Cited by 80
Nagai, K., Fukuno, S., Oda, A., & Konishi, H. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000299 · Cited by 73
The Role of Curcuma longa Against Doxorubicin (Adriamycin)-Induced Toxicity in Rats
Mohamad, R. H., El-Bastawesy, A. M., Zekry, Z. K., Al-Mehdar, H. A., Al-said, M. G. A. M., Aly, S. S., Sharawy, S. M., & El-Merzabani, M. M. (2009) · Journal of Medicinal Food · doi:10.1089/jmf.2007.0715 · Cited by 65
Theanine prevents doxorubicin-induced acute hepatotoxicity by reducing intrinsic apoptotic response
Nagai, K., Oda, A., & Konishi, H. (2015) · Food and Chemical Toxicology · doi:10.1016/j.fct.2015.02.009 · Cited by 63
The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity
Henninger, C., Huelsenbeck, J., Huelsenbeck, S. C., Grösch, S., Schad, A., Lackner, K. J., Kaina, B., & Fritz, G. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.03.012 · Cited by 62
Lamas, D., Nicoud, M. B., Sterle, H., Carabajal, E., Tesán, F., Perazzo, J. C., Cremaschi, G., Rivera, E., & Medina, V. A. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.59 · Cited by 52
Effects of N-Acetylcysteine, Deferoxamine and Selenium on Doxorubicin-Induced Hepatotoxicity
Bulucu, F., Öçal, R., Karadurmuş, N., Şahin, M., Kenar, L., Aydın, A., Öktenli, Ç., Koç, B., İnal, V., Yamanel, L., et al. (2009) · Biological Trace Element Research · doi:10.1007/s12011-009-8377-y · Cited by 49
Renu, K., & Gopalakrishnan, A. V. (2019) · Reproductive Biology · doi:10.1016/j.repbio.2019.02.004 · Cited by 49
Self-citationDifferent Growth Promoting Effects of Endophytic Bacteria on Invasive and Native Clonal Plants
Dai, Z., Fu, W. D., Wan, L., Cai, H., Wang, N., Qi, S., & Du, D. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00706 · Cited by 47
Renu, K., Sruthy, K. B., Parthiban, S., Sugunapriyadharshini, S., George, A., Pichiah, P. B. T., Suman, S., Gopalakrishnan, A. V., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.11.018 · Cited by 47
Self-citationDirks‐Naylor, A. J., Kouzi, S. A., Bero, J. D., Phan, D. T., Taylor, H. N., Whitt, S. D., & Mabolo, R. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12073 · Cited by 39
Mitochondrial Dysfunction Associated with Doxorubicin
Güven, C., Sevgiler, Y., & Taşkın, E. (2018) · InTech eBooks · doi:10.5772/intechopen.80284 · Cited by 33
Zheng, B., Wu, L., Ma, L., Liu, S., Li, L., Xie, W., & Li, X. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00058 · Cited by 31
Zolfagharzadeh, F., & Roshan, V. D. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.5.2931 · Cited by 31
The selective effect of cystathionine on doxorubicin hepatotoxicity in tumor-bearing mice
Kwiecień, I., Michalska, M., & Włodek, L. B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.09.001 · Cited by 30
Amelioration of doxorubicin induced cardio-and hepato-toxicity by carotenoids
Nair, C. K., Indu, R., Azhar, T., & Nair, A. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.131370 · Cited by 30
Effect of the oxidative stress induced by adriamycin on rat hepatocyte bioenergetics during ageing
Barogi, S., Baracca, A., Cavazzoni, M., Castelli, G. P., & Lenaz, G. (2000) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(99)00089-5 · Cited by 26
Alves, E. S., Rizo‐Roca, D., Marques‐Aleixo, I., Coxito, P. M., Martins, S., Guimarães, J. T., Oliveira, P. J., Torrella, J. R., Magalhães, J., & Ascensão, A. A. M. R. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.05.008 · Cited by 26
Hepatic Failure and Enhanced Oxidative Stress in Mitochondrial Diabetes
Takahashi, Y., Iida, K., Takeno, R., Kitazawa, R., Kitazawa, S., Kitamura, H., Fujioka, Y., Yamada, H., Kanda, F., Ohta, S., et al. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07e-091 · Cited by 14
Gotama, K. T., Soetikno, V., Louisa, M., & Arozal, W. (2019) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2019.v11s1.19099 · Cited by 9
Gao, J., Yao, P., Wu, R., Zhang, Y., Cui, X., Wei, K., & Xu, X. (2018) · Pharmacognosy Magazine · doi:10.4103/pm.pm_354_17 · Cited by 8
Cited by
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Characterization of cellular senescence in doxorubicin-induced aging mice
Sun, T., Zhang, L., Feng, J., Bao, L., Wang, J., Song, Z., Mao, Z., Li, J., & Hu, Z. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111800 · Cited by 73
Sarkar, R., Biswas, S., Ghosh, R., Samanta, P., Pakhira, S., Mondal, M., Dutta Gupta, Y., Bhandary, S., Saha, P., Bhowmik, A., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02518-0 · Cited by 69
Metadata
- Authors
- Prasanna, P. L., Renu, K., & Valsala Gopalakrishnan, A.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 250
- Pages
- 117599
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3013419261
- Cited by
- 267
- References
- 64
- FWCI
- 28.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.